Serum levels of leptin and adiponectin are not associated with disease activity or treatment response in multiple sclerosis

J Neuroimmunol. 2018 Oct 15:323:73-77. doi: 10.1016/j.jneuroim.2018.07.011. Epub 2018 Jul 24.

Abstract

Adipokines secreted by fatty tissue have inflammatory properties and are suggested biomarkers of MS disease activity. To assess this, 88 MS patients were followed with nine repeated measurements of leptin and adiponectin and 12 magnetic resonance imaging (MRI) scans for two years; six months without any immunomodulatory treatment followed by 18 months during interferon-beta (IFNB) treatment. Serum levels of leptin dropped and adiponectin increased upon initiation of IFNB-therapy, but were not associated with clinical or MRI disease activity or with treatment response. Our findings indicate that leptin and adiponectin are not useful as biomarkers of MS disease activity.

Keywords: Adipokines; Interferon-beta treatment; MRI disease activity; Multiple sclerosis; No evidence of disease activity; Treatment response.

Publication types

  • Multicenter Study
  • Randomized Controlled Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adiponectin / blood*
  • Biomarkers / blood
  • Cohort Studies
  • Disease Progression*
  • Double-Blind Method
  • Female
  • Humans
  • Immunologic Factors / therapeutic use
  • Interferon-beta / therapeutic use*
  • Leptin / blood*
  • Magnetic Resonance Imaging / trends
  • Male
  • Multiple Sclerosis / blood*
  • Multiple Sclerosis / diagnostic imaging
  • Multiple Sclerosis / drug therapy*
  • Prospective Studies
  • Treatment Outcome

Substances

  • ADIPOQ protein, human
  • Adiponectin
  • Biomarkers
  • Immunologic Factors
  • LEP protein, human
  • Leptin
  • Interferon-beta